Exelixis

Stivarga
Pharma

Bayer sells cancer drug Stivarga to Grünenthal for up to $431M

Patent protection for Stivarga is expected to last until 2029 in the EU and 2030 in the U.S., but has already expired in China.
Angus Liu Sep 21, 2026 10:20am
Go sign green light

Handa's Cabometyx formulation no threat to Exelixis: analysts

Sep 11, 2026 2:06pm
Lifeline
Favicon Fierce Biotech

Midsize biotechs form coalition to fight against MFN policy

Feb 25, 2026 1:05pm
Morrissey

Exelixis aims to be a top 5 solid tumor drugmaker in the US: CEO

Jan 16, 2026 1:00pm
Job cuts employee layoffs firings or downsizing Scissors dividing individuals positioned on colorful blocks
Favicon Fierce Biotech

Exelixis plans shuttering of East Coast site, 130 layoffs

Aug 29, 2025 9:15am
FDA

FDA recognizes 'crossover impact' on survival in Cabometyx nod

Mar 26, 2025 11:03am